How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,463 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Systemic therapy for recurrent epithelial ovarian cancer.

information on the potential harms of systemic therapy. Care has been taken in the preparation of the information contained in this report. Nevertheless, any person seeking to consult the report or apply its recommendations is expected to use independent medical judgment in the context of individual clinical circumstances or to seek out the supervision of a qualified clinician. Cancer Care Ontario (CCO) makes no representations or guarantees of any kind whatsoever regarding the report content or its use (...) Systemic therapy for recurrent epithelial ovarian cancer. Systemic therapy for recurrent epithelial ovarian cancer. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed

2017 National Guideline Clearinghouse (partial archive)

82. Systemic Therapy for Stage IV Non?Small-Cell Lung Cancer Update

factor receptor ( EGFR ), anaplastic lymphoma kinase ( ALK ), or proto-oncogene receptor tyrosine kinase ( ROS1 ) targets; and other drug classes and treatment settings that were covered in the 2015 update. Since the 2015 update, there have been many advances in the management of these patients, specifically with immune therapy with checkpoint inhibitors. Cancer immunotherapy allows some patients to live longer with a better quality of life than chemotherapy; however, not all patients respond (...) or III RCTs or meeting abstracts with fully available presentations Minimal sample size of 20 patients for immune checkpoint therapy or targeted therapy studies (50 patients for chemotherapy) Studies must have met enrollment targets Used intent-to-treat analysis for primary and secondary outcomes Independent determination of response For non-RCTs used to support recommendations, results must have been consistent Articles were excluded from the systematic review if they were meeting abstracts

2017 American Society of Clinical Oncology Guidelines

83. Chronicles of a Second Year Medical Student

Chronicles of a Second Year Medical Student Chronicles of a Second Year Medical Student – Clinical Correlations Search Chronicles of a Second Year Medical Student August 6, 2015 5 min read By Matthew Siow Peer Reviewed Day 1 of the medicine rotation: complete. I was on long call today, which meant three things. One, the hours during which I had to pretend I knew something were longer. Two, I saw a lot of things I had never seen before, from more common things like COPD exacerbations and acute (...) stem. Second, what on earth did I just read? Third, ELEVEN answer choices? Is that even legal? Seriously, who comes up with this stuff? Okay, focus. Like the awesome medical student I am, I remember reading in Harrison’s Principles of Internal Medicine about the classic triad of renal cell carcinoma: hematuria, flank pain, and a palpable mass in the flank or abdomen [1]. It has to be B. Your answer: B. Hematuria, flank pain, palpable mass Correct answer: K. There is really no classic triad

2015 Clinical Correlations

84. A Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)

, is a congenital anomaly/birth defect or is medically significant. Adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 30 days after the last dose of study drug. Number of Participants with Any Markedly Abnormal Standard Safety Laboratory Values [ Time Frame: From First dose date of study drug through 30 days after the last dose of study drug (Up to 25 months) ] Clinical (...) , their analogues, or excipients in the various formulations of any agent. Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or GI procedure that could interfere with the oral absorption or tolerance of treatment. Treatment with any investigational products within 30 days before randomization. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study

2018 Clinical Trials

85. Comparison of Therapy in Treatment of Patients With Helicobacter Pylori Infection: Concomitant Versus Hybrid Therapy.

Mestrovic, Sponsor-Investigator, University of Split, School of Medicine ClinicalTrials.gov Identifier: Other Study ID Numbers: 003-08/18-03/0001 First Posted: June 28, 2018 Last Update Posted: June 28, 2018 Last Verified: June 2018 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Antonio Mestrovic, University of Split, School of Medicine: Helicobacter pylori, eradication, hybrid therapy (...) a total of 174 patients (87 patients in each therapy group), and the planned duration is 6 months. Condition or disease Intervention/treatment Phase Helicobacter Pylori Infection Drug: Concomitant therapy Drug: Hybrid therapy Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 174 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official

2018 Clinical Trials

86. A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Ovarian Cancer Treatment With Niraparib Plus TSR-042) Study: A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer Actual Study Start Date : October 24, 2018 Estimated Primary Completion Date : November 30, 2021 Estimated Study Completion Date : July 31, 2023 Resource links provided by the National Library of Medicine related (...) hepatitis B (eg, hepatitis B surface antigen reactive) or hepatitis C (eg, hepatitis C virus ribonucleic acid [qualitative] is detected). Patient is considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease, or active, uncontrolled infection. Patient has had investigational therapy administered within 4 weeks or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to the first scheduled day

2018 Clinical Trials

87. Diarrhea Secondary to Medications

to Medications Diarrhea Secondary to Medications Aka: Diarrhea Secondary to Medications , Drug-Induced Diarrhea , Medication-Induced Diarrhea From Related Chapters II. Causes: Medication Class See s (e.g. ) s Amoxicillan-Clavulanate ( ) Chemotherapeutic agents Antiinflammatory medications S s ( ) Antihypertensives s s ( ) May cause a sprue-like not seen with other s Endocrine agents ( ) ( ) ( ) Gastrointestinal Agents or calcium containing s s (e.g. , senna) s (e.g. ) s (e.g. ) Metoclopramide (Reglan (...) Diarrhea Secondary to Medications Diarrhea Secondary to Medications Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Diarrhea Secondary

2015 FP Notebook

88. Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy

the intention-to-treat population, which included all patients in cohort 1 who were randomised and received at least 1 dose of blinded study drug (n=148 in the placebo arm and n=220 in the vedolizumab arm). The maintenance study Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 7 of 62analyses also used the intention-to-treat (...) or became intolerant to a TNF-alpha inhibitor whereas the comparator study included only those whose disease lost response or became intolerant to TNF-alpha inhibitor therapy. Results for the 'mixed' population (that is, all patients regardless of TNF-alpha inhibitor status) were provided as a secondary analysis. The company noted that the placebo response rates in GEMINI II were inexplicably higher than in the other studies and considered that this could bias the results against vedolizumab

2015 National Institute for Health and Clinical Excellence - Technology Appraisals

89. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy

cannot tolerate, or have medical contraindications for, such therapies. Golimumab is recommended only if the company provides the 100 mg dose of golimumab at the same cost as the 50 mg dose, as agreed in the patient access scheme. 1.2 The choice of treatment between infliximab, adalimumab or golimumab should be made on an individual basis after discussion between the responsible clinician and the patient about the advantages and disadvantages of the treatments available. This should take (...) and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies. 1.4 Infliximab, adalimumab or golimumab should be given as a planned course of treatment until treatment fails (including the need for surgery) or until 12 months after starting treatment, whichever is shorter. Specialists should then discuss the risks and benefits of continued treatment with the patient, and their parent or carer if appropriate: Infliximab, adalimumab and golimumab for treating

2015 National Institute for Health and Clinical Excellence - Technology Appraisals

90. Cardiovascular Disease: Secondary Prevention

Organization diagnostic criteria—who have failed to achieve an LDL 400 mg/dL. Bile acid sequestrants should be avoided for patients with TG = 300 mg/dL. • Cholestyramine has many drug interactions due to its ability to reduce absorption of other medications. Other drugs should be administered at least 1 hour before or 4–6 hours after cholestyramine. 9 ACE Inhibitor or ARB Therapy Table 3. ACE inhibitor or ARB therapy for secondary prevention of ASCVD Line Medication Initial dose Maximum dose 1 st ACE (...) ) or PCI with stent. Table 4. Antiplatelet therapy for secondary prevention of ASCVD Line Medication Initial dose Maximum dose 1 st Aspirin 81 mg daily 81 mg daily 2 nd Clopidogrel 1 75 mg daily 75 mg daily 1 Clopidogrel is equally effective in patients with ASCVD who have a contraindication or intolerance to aspirin. 10 Lowering Triglycerides to Prevent Pancreatitis Triglycerides do not require investigation or treatment unless they are higher than 500 mg/dL. (Treatment/investigation at higher than

2018 Kaiser Permanente Clinical Guidelines

91. Etelcalcetide for treating secondary hyperparathyroidism

discussion 7 Clinical effectiveness 7 Cost effectiveness 11 Equality issues 14 Pharmaceutical Price Regulation Scheme (PPRS) 2014 14 Summary of appraisal committee's key conclusions 15 5 Implementation 21 6 Appraisal committee members and NICE project team 22 Appraisal committee members 22 NICE project team 22 Etelcalcetide for treating secondary hyperparathyroidism (TA448) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page (...) Etelcalcetide is indicated for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis. Adv Adverse erse reactions reactions Very common adverse reactions with etelcalcetide are decreased blood calcium, muscle spasms, diarrhoea, nausea and vomiting. For full details of adverse reactions and contraindications, see the summary of product characteristics. Recommended Recommended dose and dose and schedule schedule The recommended initial dose of etelcalcetide is 5

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

92. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. Full Text available with Trip Pro

, double-blind study of abemaciclib/placebo (150 mg twice daily, continuous) plus nonsteroidal AI (1 mg anastrozole or 2.5 mg letrozole, daily). A total of 493 postmenopausal women with HR+, HER2- ABC with no prior systemic therapy in this setting were enrolled. The primary endpoint was investigator-assessed PFS (final analysis after 240 events); other endpoints included response and safety evaluations. Here we analyze the final PFS data and update secondary endpoints. The abemaciclib arm had (...) MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. At the MONARCH 3 interim analysis, abemaciclib plus a nonsteroidal aromatase inhibitor (AI) significantly improved progression-free survival (PFS) and objective response rate (ORR) with a tolerable safety profile as initial treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). MONARCH 3 is a randomized, phase III

2019 NPJ breast cancer Controlled trial quality: predicted high

93. Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTTO Trial. Full Text available with Trip Pro

Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTTO Trial. We investigated the pattern of rash, diarrhea, and hepatic adverse events (AEs) secondary to lapatinib and their association with age and pathologic complete response (pCR) in the Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (NeoALLTO) phase III trial.Patients with HER2-positive early breast cancer were (...) assigned to arms A and C were eligible (n = 306). Younger patients (≤ 50 years) experienced significantly more rash compared with older patients (74.4% v 47.9%; P < .0001). Diarrhea and hepatic AEs were observed in 78.8% and 41.2% of patients, respectively, with no differences in rate or severity or time of onset according to age. Early rash (ie, before starting paclitaxel) was independently associated with a higher chance of pCR, mainly in patients older than 50 years (odds ratio [OR] = 3.76; 95% CI

2013 Journal of Clinical Oncology Controlled trial quality: uncertain

94. Oral Phage Therapy of Acute Bacterial Diarrhea With Two Coliphage Preparations: A Randomized Trial in Children From Bangladesh. Full Text available with Trip Pro

Oral Phage Therapy of Acute Bacterial Diarrhea With Two Coliphage Preparations: A Randomized Trial in Children From Bangladesh. Antibiotic resistance is rising in important bacterial pathogens. Phage therapy (PT), the use of bacterial viruses infecting the pathogen in a species-specific way, is a potential alternative.T4-like coliphages or a commercial Russian coliphage product or placebo was orally given over 4 days to Bangladeshi children hospitalized with acute bacterial diarrhea. Safety (...) children, but the titers did not show substantial intestinal phage replication (secondary microbiology outcome). 60% of the children suffered from a microbiologically proven E. coli diarrhea; the most frequent diagnosis was ETEC infections. Bacterial co-pathogens were also detected. Half of the patients contained phage-susceptible E. coli colonies in the stool. E. coli represented less than 5% of fecal bacteria. Stool ETEC titers showed only a short-lived peak and were otherwise close

2016 EBioMedicine Controlled trial quality: uncertain

95. Truberzi (eluxadoline) - for the treatment of adults who have irritable bowel syndrome with diarrhoea

index BSS Bristol Stool Scale CHMP Committee for Medicinal Products for Human Use Cmax maximum observed plasma concentration CNS central nervous system CSR clinical study report EMA European Medicines Agency EU European Union FDA US Food and Drug Administration GERD gastroesophageal reflux disease GI gastrointestinal IBS irritable bowel syndrome IBS-d diarrhea-predominant irritable bowel syndrome IBS-m irritable bowel syndrome, where a mixture of constipation and diarrhea is predominant IBS-QoL (...) Truberzi (eluxadoline) - for the treatment of adults who have irritable bowel syndrome with diarrhoea 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 21 July 2016 EMA/549473/2016 Committee for Medicinal Products for Human Use

2016 European Medicines Agency - EPARs

96. Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy

published an evidence summary on zonisamide monotherapy for treating partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy in April 2013 (ESNM17). This evidence summary is based on a phase III double-blind RCT that assessed the efficacy and safety of adjunctive zonisamide therapy in 207 children and young people with partial epilepsy (Guerrini et al. 2013). This trial was the main efficacy study assessed by the European Medicines Agency when a licence (...) . The death was considered to be possibly treatment related: the young person (a 14-year-old male) experienced weight loss and diarrhoea which weakened their general condition to such an extent they were unable to take their anti-epileptic medications. This triggered a fatal episode of status Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy (ESNM37) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions

2014 National Institute for Health and Clinical Excellence - Advice

97. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial (Abstract)

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial VEGF and VEGF receptor 2 (VEGFR-2)-mediated signalling and angiogenesis can contribute to the pathogenesis and progression of gastric cancer. We aimed to assess whether the addition of ramucirumab, a VEGFR-2 antagonist monoclonal antibody, to first-line chemotherapy improves outcomes (...) a central review of CT scans. Overall survival was a key secondary endpoint. This study is registered with ClinicalTrials.gov, number NCT02314117.Between Jan 28, 2015, and Sept 16, 2016, 645 patients were randomly assigned to receive ramucirumab plus fluoropyrimidine and cisplatin (n=326) or placebo plus fluoropyrimidine and cisplatin (n=319). Investigator-assessed progression-free survival was significantly longer in the ramucirumab group than the placebo group (hazard ratio [HR] 0·753, 95% CI 0·607-0

2019 EvidenceUpdates

98. Acute diarrhoea in children: racecadotril as an adjunct to oral rehydration

primary care. The majority of children in the UK recover from acute diarrhoea without treatment or by using ORS solution alone. Although adjunctive therapy with racecadotril appears to be effective and well tolerated, it is unclear which children would benefit from it and whether it is cost effective. A UK cost-effectiveness analysis (Rautenberg et al. 2012) has been published. It is not discussed here because cost-effectiveness analyses are outside the scope for Evidence summaries: new medicines (...) manage an episode of acute diarrhoea affecting their child at home, and in some cases without seeking professional advice. However, many parents and carers do seek advice from healthcare professionals. In a UK study (Armon et al. 2001), diarrhoeal illness accounted for 16% of medical presentations to a major paediatric accident and emergency department. The NICE clinical guideline on diarrhoea and vomiting in children under 5 advises that the usual duration of diarrhoea is 5–7 days and in most

2013 National Institute for Health and Clinical Excellence - Advice

99. Acute diarrhoea in adults: racecadotril

and gastroenteritis, particularly in frail and older people. The British national formulary (BNF) advises that antimotility drugs may be used to relieve symptoms of uncomplicated acute diarrhoea in adults; it may also be necessary to use oral rehydration salt (ORS) solution. Faecal incontinence: the management of faecal incontinence in adults (NICE clinical guideline 49) advises that antidiarrhoeal medication should be offered to people with faecal incontinence associated with loose stools once other causes (...) (such as excessive laxative use, dietary factors and other medication) have been excluded. The BNF advises that antispasmodics are occasionally of value in treating abdominal cramp associated with diarrhoea but they should not be used for primary treatment. Antibacterial drugs are generally unnecessary in simple gastroenteritis because the complaint usually resolves quickly Acute diarrhoea in adults: racecadotril (ESNM11) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk

2013 National Institute for Health and Clinical Excellence - Advice

100. Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs

an alternative biologic therapy; Patients switching to a biosimilar (or starting a new cycle with the equivalent legacy drug), successfully completed and exited a previous course of therapy with the equivalent legacy drug. Exclusion Criteria: Under 18 years of age No clinical diagnosis of inflammatory rheumatic disease (either RA or AS), or IBD (CD or UC) Refused to participate or sign informed consent Contacts and Locations Go to Information from the National Library of Medicine To learn more about (...) and worldwide there is a need for updated independent real-world comparative effectiveness and safety data related to biologic drugs including biosimilar drugs. Biosimilar drugs hold potential to improve access to needed therapies at reduced cost enabling savings to be reallocated to other needs. However updated real-world evidence on comparative effectiveness and safety of biosimilar drugs is lacking. Investigators aim to demonstrate feasibility of creating network of clinical cohorts and other resources

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>